Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
Titel:
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
Auteur:
Stintzing, S. Wirapati, P. Lenz, H.-J. Neureiter, D. Fischer von Weikersthal, L. Decker, T. Kiani, A. Kaiser, F. Al-Batran, S. Heintges, T. Lerchenmüller, C. Kahl, C. Seipelt, G. Kullmann, F. Moehler, M. Scheithauer, W. Held, S. Modest, D.P. Jung, A. Kirchner, T. Aderka, D. Tejpar, S. Heinemann, V.